FrancophonIA/ELRC3.0 huggingface dataset:
English: The average liraglutide steady state concentration (AUCτ/24) reached approximately 31 nmol/L in obese (BMI 30-40 kg/m2) patients following administration of 3 mg liraglutide.
Slovenian: povprečna koncentracija liraglutida v stanju dinamičnega ravnovesja (AUCτ/24) dosegla približno 31 nmol/l.
English: After first use of the pen, store below 30°C or in a refrigerator Keep the pen cap on in order to protect from light
Slovenian: Po prvi uporabi shranjujte injekcijski peresnik pri temperaturi do 30 °C ali v hladilniku.
English: Driving or use of machines should be exercised with caution if dizziness occurs.
Slovenian: Če se pojavi omotica, je pri upravljanju vozil in strojev potrebna previdnost.
English: Hold the dose button down until the dose counter shows 0.
Slovenian: Potisni gumb držite pritisnjen, dokler se na števcu odmerka ne pokaže 0.
English: Table 3 Trial 1: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 56
Slovenian: Preglednica 3 (preskušanje 1): Spremembe telesne mase, glikemije in srčno-presnovnih parametrov po 56 tednih glede na izhodišče
English: • Keep the needle in your skin after the dose counter has returned to 0
Slovenian: • Ko se števec odmerka vrne na 0, iglo pustite v koži in počasi štejte do 6.
English: • Inflamed gall bladder
Slovenian: • vnetje žolčnika
English: This may be due to feeling sick (nausea), being sick (vomiting) and diarrhoea.
Slovenian: v primeru občutka slabosti (siljenja na bruhanje), bruhanja in driske.
English: Always use the dose counter and the dose pointer to see how many mg you have selected before injecting this medicine.
Slovenian: Pred injiciranjem zdravila s števcem odmerka in kazalnikom odmerka vedno preverite, koliko mg ste izbrali.
English: 1.8 mg once a day
Slovenian: 1,8 mg enkrat na dan teden 4
English: Once you start using the pen:
Slovenian: Ko injekcijski peresnik začnete uporabljati
English: Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with GLP-1 receptor agonists.
Slovenian: Pri bolnikih, ki so se zdravili z agonisti receptorjev GLP-1, so bili opisani znaki in simptomi dehidracije, vključno z okvaro ledvic in akutno odpovedjo ledvic.
English: 0.6 mg once a day
Slovenian: 0,6 mg enkrat na dan teden 2
English: The dose should be increased to 3.0 mg once daily in increments of 0.6 mg with at least one week intervals to improve gastro-intestinal tolerability (see table 1).
Slovenian: Končni odmerek 3,0 mg enkrat na dan je treba doseči postopoma, v korakih po 0,6 mg, da bi izboljšali prenašanje v prebavilih.
English: Increased lipase
Slovenian: Preiskave povečana koncentracija lipaze,
English: In clinical trials, tachycardia was reported in 0.6% of patients treated with Saxenda and in 0.1% of patients treated with placebo.
Slovenian: V kliničnih preskušanjih so o tahikardiji poročali pri 0,6 % bolnikov, zdravljenih z zdravilom
English: tmax was delayed by 1.5 h with liraglutide for both compounds.
Slovenian: Pri sočasnem zdravljenju z liraglutidom se je tmax pri obeh učinkovinah podaljšal za 1,5 ure.
English: This is more likely to occur at the start of treatment and may be due to being sick (vomiting), feeling sick (nausea) and diarrhoea
Slovenian: Občasni: pojavijo se lahko pri največ 1 od 100 bolnikov • izguba tekočine (dehidracija); bolj verjetno je, da se pojavi na začetku zdravljenja in je lahko posledica bruhanja, siljenja na bruhanje (slabost) in driske
English: The pen can dial up to a maximum of 3.0 mg.
Slovenian: Z injekcijskim peresnikom lahko izberete največ 3,0 mg.
English: Digoxin median tmax was delayed from 1 h to 1.5 h. No dose adjustment of digoxin is required based on these results.
Slovenian: Mediani tmax digoksina se je podaljšal z 1 na 1,5 ure.
English: Some severe allergic reactions (anaphylaxis) have been reported rarely in patients using Saxenda.
Slovenian: Pri bolnikih, zdravljenih z zdravilom Saxenda, so poročali o redkih primerih hude alergijske reakcije (anafilaksija).
English: Liraglutide did not change the overall exposure of griseofulvin following administration of a single dose of griseofulvin 500 mg. Griseofulvin Cmax increased by 37% while median tmax did not change.
Slovenian: Cmax griseofulvina se je povečala za 37 %, medtem ko se mediani tmax ni spremenil.
English: Exposure was significantly lower (44%) in patients with severe hepatic impairment (Child Pugh score >9).
Slovenian: Izpostavljenost je bila bistveno nižja (44 %)
English: Proportion of patients losing >10% body weight at week 160, % (95% CI)
Slovenian: Delež bolnikov, ki so izgubili > 10 % telesne mase do 160. tedna v % (95 % IZ)
English: Few cases of anaphylactic reactions with symptoms such as hypotension, palpitations, dyspnoea and oedema have been reported with marketed use of liraglutide.
Slovenian: Po prihodu liraglutida na trg so v nekaj primerih poročali o anafilaktični reakciji, ki so jo spremljali simptomi, kot so hipotenzija, palpitacije, dispneja in edem.
English: Nausea Vomiting Diarrhoea Constipation
Slovenian: Bolezni živčevja omotica, disgevzija
English: Only doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3.0 mg must be selected with the dose selector.
Slovenian: 1,8 mg, 2,4 mg ali 3,0 mg. Da zagotovite pravilen odmerek, mora biti izbrani odmerek natančno poravnan s kazalnikom odmerka.
English: Neonatal growth was reduced in rats while exposed to liraglutide and persisted in the post-weaning period in the high dose group.
Slovenian: Pri podganah, ki so bile izpostavljene liraglutidu, se je upočasnila neonatalna rast, kar se je v skupini, ki je prejemala velik odmerek,
English: Stop taking Saxenda and contact a doctor immediately if you notice any of the following serious side effects:
Slovenian: Če opazite katerega koli od naslednjih resnih neželenih učinkov, zdravilo Saxenda prenehajte uporabljati in se nemudoma posvetujte z zdravnikom:
English: Liraglutide did not change the overall exposure of paracetamol following a single dose of 1,000 mg. Paracetamol Cmax was decreased by 31% and median tmax was delayed up to 15 min. No dose adjustment for concomitant use of paracetamol is required.
Slovenian: Največja koncentracija paracetamola (Cmax) se je zmanjšala za 31 %, mediani čas do največje koncentracije (tmax) pa se je podaljšal za največ 15 min.
English: When starting treatment with Saxenda, you may lose body fluid or become dehydrated.
Slovenian: Izguba tekočine in dehidracija Po uvedbi zdravljenja z zdravilom Saxenda se lahko pojavi izguba telesne tekočine (dehidracija), npr.
English: Instructions on how to use Saxenda 6 mg/ml solution for injection in prefilled pen
Slovenian: Navodila za uporabo zdravila Saxenda 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
English: Example
Slovenian: Sprememba
English: Proportion of patients losing >10% body weight at week 56, % (95% CI) Full Analysis Set.
Slovenian: telesne mase do 56. tedna v % (95 % IZ) Celotni nabor za analizo.
English: Saxenda (N=180) Placebo (N=179) Saxenda vs. placebo
Slovenian: Placebo (N=179)
English: Treatment with liraglutide significantly reduced the severity of obstructive sleep apnoea as assessed by change from baseline in the AHI compared with placebo (table 6).
Slovenian: ocenjene kot sprememba od izhodiščnega AHI v primerjavi s placebom (preglednica 6).
English: • Faster pulse.
Slovenian: • zvišan srčni utrip
English: Figure 2 Cumulative distribution of weight change (%) after 56 weeks of treatment in trial 1 Table 5 Trial 2: Changes from baseline in body weight, glycaemia and cardiometabolic parameters at week 56
Slovenian: Slika 2 Kumulativna porazdelitev spremembe telesne mase (%) po 56 tednih zdravljenja v preskušanju 1
English: Disodium phosphate dihydrate Propylene glycol
Slovenian: - Druge sestavine zdravila so natrijev hidrogenfosfat dihidrat, propilenglikol, fenol,
English: Age had no clinically relevant effect on the pharmacokinetics of liraglutide based on the results from a population pharmacokinetic analysis of data from overweight and obese patients (18 to 82 years).
Slovenian: Glede na rezultate populacijske farmakokinetične analize podatkov bolnikov s prekomerno telesno maso in bolnikov z debelostjo (starih od 18 do 82 let) starost ne vpliva klinično pomembno na farmakokinetiko liraglutida.
English: Solution for injection
Slovenian: Vzdrževanje injekcijskega peresnika
English: 1.2 mg once a day
Slovenian: 1,2 mg enkrat na dan teden 3
English: 1 pen 3 pens 5 pens
Slovenian: 1 injekcijski peresnik 3 injekcijski peresniki 5 injekcijskih peresnikov
English: Pancreatitis*** Delayed gastric emptying****
Slovenian: žolčnika in žolčevodov holelitiaza***
English: Proportion of patients losing ≥5% body weight at week 56, % (95% CI)
Slovenian: ≥ 5 % telesne mase do 56. tedna v % (95 % IZ)
English: Saxenda is not recommended for use in patients with severe renal impairment (creatinine clearance <30 ml/min) including patients with end-stage renal disease (see sections 4.4, 4.8 and 5.2).
Slovenian: Zdravljenje z zdravilom Saxenda ni priporočljivo pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min), vključno z bolniki s končno odpovedjo ledvic
English: Proportion of patients losing ≥5% body weight at week 160, % (95% CI)
Slovenian: Delež bolnikov, ki so izgubili ≥ 5 % telesne mase do 160. tedna v % (95 % IZ) 49,6
English: This is because the effects and safety of this medicine have not been studied in this age group.
Slovenian: Zdravila Saxenda ne uporabljajte pri otrocih in mladostnikih, mlajših od 18 let, saj učinkovitost in varnost zdravila v tej starostni skupini še nista raziskani.
English: Only if trained or advised by your doctor or nurse, you may split your dose between your current pen and a new pen.
Slovenian: Če potrebujete več zdravila, kot ga je preostalo v injekcijskem peresniku Odmerek lahko razdelite med obstoječi in novi injekcijski peresnik le, če vas je tega naučil ali vam tako svetoval zdravnik ali medicinska sestra.
English: Mean change at week 160, % (95% CI) Mean change at week 160, kg (95% CI)
Slovenian: 160 tednih v kg (95 % IZ)
English: Saxenda 6 mg/ml solution for injection in pre-filled pen liraglutide
Slovenian: Saxenda 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku liraglutid
English: Injection site reactions Asthenia Fatigue
Slovenian: Bolezni imunskega sistema anafilaktična reakcija
English: Superior weight loss was achieved with liraglutide compared to placebo in obese/overweight patients in all groups studied.
Slovenian: V vseh preučevanih skupinah je bila pri bolnikih z debelostjo ali s prekomerno telesno maso dosežena večja izguba telesne mase z liraglutidom kot s placebom.
English: Dose injected
Slovenian: Izpuščeni odmerek
English: Figure 3 Change from randomisation (week 0) in body weight (%) by time in trial 4
Slovenian: Slika 3 Spremembe telesne mase (%) v času od randomizacije (teden 0) dalje v preskušanju 4 Pred tednom 0 so bili bolniki zdravljeni z nizkokalorično dieto in telesno vadbo.
English: FPG=fasting plasma glucose.
Slovenian: Koncentracija glukoze v plazmi na tešče v mmol/l
English: Saxenda (N=412) Placebo (N=211) Saxenda vs. placebo
Slovenian: Placebo (N=211)
English: Saxenda (N=2437) Placebo (N=1225) Saxenda vs. placebo
Slovenian: Placebo (N=1225)
English: Saxenda 6 mg/ml solution for injection in pre-filled pen
Slovenian: Saxenda 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
English: Example 0.6 mg selected
Slovenian: 0,6 mg
English: The contraceptive effect is therefore anticipated to be unaffected when co-administered with liraglutide.
Slovenian: Ni verjetno, da bi sočasno zdravljenje z liraglutidom vplivalo na kontracepcijski učinek.
English: Mean change at week 56, % (95% CI) Mean change at week 56, kg (95% CI)
Slovenian: 56 tednih v kg (95 % IZ)
English: Loss of fluid and dehydration
Slovenian: Presnovne in prehranske motnje hipoglikemija*
English: 2.4 mg left
Slovenian: 2,4 mg
English: If you have liver problems, consult your doctor.
Slovenian: Posvetujte se z zdravnikom, če imate težave z jetri.
English: Proportion of patients losing >10% body weight at week 56, % (95% CI)
Slovenian: > 10 % telesne mase do 56. tedna v % (95 % IZ)
English: 2.4 mg once a day
Slovenian: 2,4 mg enkrat na dan teden 5 in naprej
English: It contains 18 mg of liraglutide and delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg.
Slovenian: Vsebuje 18 mg liraglutida in z njim lahko injicirate odmerke po 0,6 mg, 1,2 mg, 1,8 mg, 2,4 mg in 3,0 mg. Injekcijski peresnik je namenjen uporabi z injekcijskimi iglami NovoFine ali NovoTwist za enkratno uporabo, dolžine do 8 mm in ne tanjšimi kot 32G.
English: If the solution looks cloudy, do not use the pen.
Slovenian: Če je raztopina motna, injekcijskega peresnika ne uporabite.
English: when you use these medicines with Saxenda.
Slovenian: Kako uporabljati zdravilo Saxenda Pri uporabi tega zdravila natančno upoštevajte navodila zdravnika.
English: Start by checking your pen to make sure that it contains Saxenda 6 mg/ml,
Slovenian: Najprej preverite, če injekcijski peresnik vsebuje zdravilo Saxenda 6 mg/ml, nato pa se s pomočjo slik v nadaljevanju seznanite z različnimi deli injekcijskega peresnika in igle.
English: Hepatic impairment
Slovenian: Vnetje trebušne slinavke
English: Package leaflet: Information for the patient Saxenda 6 mg/ml solution for injection in pre-filled pen liraglutide
Slovenian: Navodilo za uporabo Saxenda 6 mg/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku liraglutid
English: Batch
Slovenian: Tahikardija
English: The frequency is not known.
Slovenian: Pogostnost ni znana.
English: 31 May 2016 EMA/262389/2016
Slovenian: 31. maj 2016 EMA/262389/2016
English: However, firm conclusions could not be drawn as these studies did not use a control group.
Slovenian: Vendar trdnih zaključkov ni bilo mogoče sprejeti, ker v teh študijah niso bile uporabljene kontrolne skupine.
English: Some of these combinations may be used in adults and adolescents over 12 years of age, some others may be used also in children over 4 years of age.
Slovenian: Nekatere izmed teh kombinacij se smejo uporabljati pri odraslih in mladostnikih, starejših od 12 let, druge pa tudi pri otrocih, starejših od 4 let.
English: What are the HMPC conclusions on their medicinal uses?
Slovenian: Kakšne so ugotovitve odbora HMPC v zvezi z medicinsko uporabo?
English: Thymus vulgaris L. or Thymus zygis L., herba and Primula veris L. or Primula elatior (L.) Hill, radix
Slovenian: Thymus vulgaris L. ali Thymus zygis L., herba, in Primula veris L. ali Primula elatior (L.) Hill, radix
English: In some cases the solvent is then either partially or fully evaporated to obtain a soft or dry extract.
Slovenian: V nekaterih primerih se topilo nato delno ali v celoti odpari, s čimer se pridobi gosti ali suhi ekstrakt.
English: Stomach complaints and nausea may occur.
Slovenian: Pojavijo se lahko želodčne težave in siljenje na bruhanje.
English: Further information on the risks associated with these thyme and primula root medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Slovenian: Dodatne informacije o tveganjih, povezanih s temi zdravili, ki vsebujejo zel vrtne materine dušice in korenino jegliča, vključno z ustreznimi previdnostnimi ukrepi za njihovo varno uporabo, so na voljo v monografiji na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: The HMPC conclusions only cover combinations of certain thyme and primula root preparations which are obtained using a technique to extract compounds by putting the plant material in a solvent (such as ethanol or glycerol) to dissolve compounds and form a liquid extract.
Slovenian: Zaključki odbora HMPC zajemajo samo kombinacije določenih pripravkov z zeljo vrtne materine dušice in korenino jegliča, ki se pridobivajo z uporabo tehnike, s katero se spojine ekstrahirajo tako, da se rastlinski material najprej namoči v topilo (npr. etanol ali glicerol), v katerem se raztopijo spojine in se pridobi tekoči ekstrakt.
English: This summary is not intended to provide practical advice on how to use medicines containing combinations of thyme and primula root.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo kombinacijo zeli vrtne materine dušice in korenine jegliča.
English: Herbal medicines containing combinations of these thyme and primula root preparations are usually available in liquid or solid forms to be taken by mouth.
Slovenian: Zdravila rastlinskega izvora, ki vsebujejo kombinacije teh pripravkov z zeljo vrtne materine dušice in korenino jegliča, so navadno na voljo v tekoči ali trdni obliki za jemanje skozi usta.
English: In its assessment, the HMPC considered a number of clinical studies with thyme and primula root showing that these medicines help reduce coughs in adults.
Slovenian: V svoji oceni je odbor HMPC upošteval več kliničnih študij z zeljo vrtne materine dušice in korenino jegliča, ki so pokazale, da ta zdravila pomagajo zmanjševati kašelj pri odraslih.
English: Thyme is the common name for the aerial parts of the plants Thymus vulgaris L. or Thymus zygis L., and primula root is the common name for the underground parts of Primula veris L. or Primula elatior (L.) Hill.
Slovenian: Zel vrtne materine dušice je splošno ime za nadzemne dele rastline Thymus vulgaris L. ali Thymus zygis L., korenina jegliča pa je splošno ime za podzemne dele rastline Primula veris L. ali Primula elatior (L.) Hill.
English: How do thyme and primula root work as a medicine?
Slovenian: Kako zel vrtne materine dušice in korenina jegliča delujeta kot zdravilo?
English: Information on the use and licensing of thyme and primula root medicines in EU Member States should be obtained from the relevant national authorities.
Slovenian: Za informacije o uporabi in registraciji zdravil, ki vsebujejo zel vrtne materine dušice in korenino jegliča, v državah članicah EU se obrnite na pristojni nacionalni organ.
English: The way thyme and primula root work is not fully known, but laboratory studies indicate that thyme may have an action against microbes and a muscle relaxant effect while primula root may increase production of sputum in the airways, thereby diluting phlegm and helping to bring it up.
Slovenian: Način delovanja zeli vrtne materine dušice in korenine jegliča ni v celoti znan, vendar laboratorijske študije kažejo, da zel vrtne materine dušice morda deluje protimikrobno in sprošča mišice, korenina jegliča pa morda povečuje nastajanje izmečka v dihalih ter tako redči sluz in pomaga pri izkašljevanju.
English: Any applications for the licensing of medicines containing combinations of thyme and primula root have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Slovenian: Vlogo za izdajo dovoljenja za promet z zdravili, ki vsebujejo kombinacijo zeli vrtne materine dušice in korenine jegliča, je treba predložiti pristojnemu nacionalnemu organu za zdravila, ki bo to vlogo za izdajo dovoljenja za promet z zdravilom rastlinskega izvora ocenil in upošteval znanstvene zaključke odbora HMPC.
English: Further information on the HMPC assessment of thyme and primula root medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Slovenian: Dodatne informacije o oceni zdravil, ki vsebujejo zel vrtne materine dušice in korenino jegliča, ki jo je opravil odbor HMPC, vključno z njegovimi znanstvenimi zaključki, so na voljo na spletni strani agencije pod zavihkom „Vsi dokumenti“: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: If symptoms last longer than one week during the use of the medicine for coughs associated with colds a doctor or a qualified health care practitioner should be consulted.
Slovenian: Če simptomi med uporabo zdravila pri kašlju, povezanem s prehladom, trajajo dlje kot en teden, se je treba posvetovati z zdravnikom ali usposobljenim zdravstvenim delavcem.
English: If symptoms last longer than one week during the use of the medicine for chesty coughs a doctor or pharmacist should be consulted.
Slovenian: Če simptomi med uporabo zdravila pri mokrem kašlju trajajo dlje kot en teden, se je treba posvetovati z zdravnikom ali farmacevtom.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of thyme and primula root as a combination.
Slovenian: To je povzetek znanstvenih zaključkov Odbora za zdravila rastlinskega izvora (HMPC) v zvezi z medicinsko uporabo kombinacije zeli vrtne materine dušice in korenine jegliča.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing thyme herb and primula root combinations.
Slovenian: Ugotovitve odbora HMPC države članice EU upoštevajo pri ocenjevanju vlog za izdajo dovoljenja za promet z zdravili rastlinskega izvora, ki vsebujejo kombinacijo zeli vrtne materine dušice in korenine jegliča.
English: Detailed instructions on how to take thyme and primula root medicines and who can use them can be found in the package leaflet that comes with the medicine.
Slovenian: Podrobna navodila o jemanju zdravil, ki vsebujejo zel vrtne materine dušice in korenino jegliča, in o tem, kdo sme ta zdravila jemati, so na voljo v navodilu za uporabo, ki je priloženo posameznemu zdravilu.
English: Thyme and primula root preparations may also be found in additional combinations with other herbal substances in some herbal medicines.
Slovenian: Pripravki z zeljo vrtne materine dušice in korenino jegliča so v nekaterih zdravilih rastlinskega izvora lahko na voljo tudi v kombinaciji z drugimi rastlinskimi snovmi.
English: For more information about treatment with thyme and primula root medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravili, ki vsebujejo zel vrtne materine dušice in korenino jegliča, preberite navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujte z zdravnikom ali farmacevtom.
English: The HMPC concluded that certain thyme and primula root preparations can be used as an expectorant (a medicine that helps bring up phlegm) for productive (chesty) coughs in adults.
Slovenian: Odbor HMPC je zaključil, da se lahko določeni pripravki z zeljo vrtne materine dušice in korenino jegliča uporabljajo kot ekspektoransi (zdravila za lažje izkašljevanje sluzi) pri produktivnem (mokrem) kašlju pri odraslih.
English: What are thyme and primula root?
Slovenian: Kaj sta zel vrtne materine dušice in korenina jegliča?
English: In its assessment, the HMPC also considered clinical studies with thyme and primula root medicines in children.
Slovenian: V svoji oceni je odbor HMPC prav tako upošteval klinične študije z zdravili, ki vsebujejo zel vrtne materine dušice in korenino jegliča, pri otrocih.
English: The HMPC conclusions on the use of certain thyme and primula root preparations for productive coughs are based on their ‘well-established use'.
Slovenian: Zaključki odbora HMPC v zvezi z uporabo določenih pripravkov z zeljo vrtne materine dušice in korenino jegliča pri produktivnem kašlju temeljijo na njihovi „dobro uveljavljeni medicinski uporabi“.
English: For practical information about using thyme and primula root combination medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o njihovi uporabi naj bolniki preberejo navodilo za uporabo, ki je priloženo posameznemu zdravilu, ali se posvetujejo z zdravnikom ali farmacevtom.